Morgan Roupret(@MRoupret) 's Twitter Profileg
Morgan Roupret

@MRoupret

Professor of Urology @HopPitieSalpe @APHP @Sorbonne_Univ_ Paris France 🇫🇷 Editor-in-Chief @EurUrolOncol @Uroweb & CCAFU chairman @AFUrologie - Views my own

ID:184405393

linkhttps://euoncology.europeanurology.com/ calendar_today29-08-2010 13:32:50

11,9K Tweets

6,5K Followers

862 Following

UroToday.com(@urotoday) 's Twitter Profile Photo

Exploring the Future of Treatment! Join Morgan Roupret Hôpital Pitié Salpêtrière - AP-HP and Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center as they delve into the latest advancements, from erdafitinib's promise to chemoablation concepts, they discuss the evolving landscape of care > bit.ly/48mLERk

Exploring the Future of #NMIBC Treatment! Join @MRoupret @HopPitieSalpe and @UroDocAsh @MDAndersonNews as they delve into the latest advancements, from erdafitinib's promise to chemoablation concepts, they discuss the evolving landscape of care > bit.ly/48mLERk
account_circle
World of Statistics(@stats_feed) 's Twitter Profile Photo

✈️ Top revenue-generating flight routes in 2023:

🇦🇺 Sydney to Melbourne 🇦🇺: $1.21B
🇺🇸 New York to London 🇬🇧: $1.15B
🇸🇦 Riyadh to Jeddah 🇸🇦: $1.03B
🇦🇪 Dubai to Riyadh 🇸🇦: $990M
🇺🇸 Los Angeles to New York 🇺🇸: $801M
🇺🇸 San Francisco to Newark 🇺🇸: $722M
🇺🇸 Newark to Los Angeles 🇺🇸:…

account_circle
Tom Powles(@tompowles1) 's Twitter Profile Photo

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47)

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24
account_circle
UroToday.com(@urotoday) 's Twitter Profile Photo

Patient with non-invasive, HG upper tract disease in setting of prior radical cystectomy – What is optimal management? What if GFR ~ 50 instead of 80? Morgan Roupret Sarah P. Psutka MD MS Arnulf Stenzl. written coverage by Rashid K. Sayyid > bit.ly/3PReMsC Ashish M. Kamat, MD, MBBS

#RapidFireDebate Patient with non-invasive, HG upper tract disease in setting of prior radical cystectomy – What is optimal management? What if GFR ~ 50 instead of 80? @MRoupret @spsutkaMD @AStenzl. #EAU24 written coverage by @RKSayyid > bit.ly/3PReMsC @UroDocAsh
account_circle
Stacy Loeb, MD(@LoebStacy) 's Twitter Profile Photo

So excited to participate in the plenary today w Kari Tikkinen & Annemarie Leliveld on the best way to reduce carbon footprint in urology! Thanks European Association of Urology (EAU) for highlighting environmental sustainability!! So timely for 🌍🌱

So excited to participate in the #eau24 plenary today w @KariTikkinen & @AMLeliveld on the best way to reduce carbon footprint in urology! Thanks @Uroweb for highlighting environmental sustainability!! So timely for #EarthMonth 🌍🌱
account_circle
Laura Caba(@Caba_L) 's Twitter Profile Photo

Opening Plenary- “Controversies in GU cancer staging” chaired by Morgan Roupret Walz

Brian F. Chapin highlights currently available biomarkers for newly diagnosed PCa patients

#EAU24 Opening Plenary- “Controversies in GU cancer staging” chaired by @MRoupret @Walzjc @ChapinMD highlights currently available biomarkers for newly diagnosed PCa patients
account_circle